The 28th ESACT meeting will take place on June 23-26, 2024 in Edinburgh.
More details on the 28th ESACT meeting →
Abstract submission is open now!
Submit your abstract here until January 10th 2024. Outcomes on oral and poster submissions is March 8th 2024.
Registration for meeting attendance will open on October 23rd 2024.
Confirmed invited speakers
Confirmed invited speakers (with draft titles) include:
Adrian Bird (University of Edinburgh, UK) – Towards genetic therapies for Rett syndrome
David MacMillan (Princeton, USA) – Micromapping: A chemical approach to biological insights and therapeutic intervention
Nabila Saklaven (Cellino, USA) – Ultra-scalable Manufacturing of Induced Pluripotent Stem Cell for Therapies
Cells as factories and therapies: modernizing biologics production for emerging modalities
Andreas Pluckthun (University of Zurich) – Precision gene delivery through protein engineering
Isabelle Riviere (Takeda, USA) – Evolving CAR cell Therapies
Zoltan Ivics (Paul Ehrlich Institute, Frankfurt) – The Sleeping Beauty transposon system: A molecular parasite tamed for genome engineering
Product Quality – Functional Relevance and Emerging Technologies
Jamie Piret (UBC, Canada) – Process Analytical Utility of Raman Microscopy for Cell Therapy Manufacturing
Jonathan Bones (NIBRT, Ireland) – Making analytical characterisation routine
Rena Mizrahi (Gigagen, USA) – Control and Characterization of Thousands-Diverse Recombinant Polyclonal Antibodies
From Big Data to Better Cells and Processes
Moritz von Stosch (DataHow, Switzerland) – Towards digital process development – How (hybrid) modeling and transfer learning could change the way we develop and operate processes
Zan Luthney-Schulten (University of Illinois, USA) – 4D simulations of a growing minimal bacterial cell
Transitioning from development to manufacture – How do science and innovation translate into highly efficient biomanufacturing?
Brian Shy (University of California, USA) – Developing and manufacturing CRISPR-engineered T cell therapies in the academic setting
Cath Green (University of Oxford, UK) – Scaling-up Covid vaccine manufacture: Combating the pandemic
Jyothsna Viswesvaraiah (Seismic, USA) – Mitigating risk during biologics manufacturing using discovery stage developability assays and state of the art machine learning based optimization